Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5941
    -0.0008 (-0.14%)
     
  • NZD/EUR

    0.5549
    +0.0009 (+0.16%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    94.0360
    +1.5400 (+1.66%)
     

Worldwide Hydrogel-based Drug System Industry to 2027 - Therapeutic Values of the Hydrogel-based Drug Delivery System are Driving Growth

Dublin, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Hydrogel-based Drug System Market By Polymer Origin (Synthetic, Natural and Hybrid), By Delivery Route (Ocular, Subcutaneous, Oral Cavity, Topical and Other Delivery Routes), By Regional Outlook, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

The Global Hydrogel-based Drug Delivery System Market size is expected to reach $9.3 billion by 2027, rising at a market growth of 8% CAGR during the forecast period.

Hydrogel refers to the three-dimensional polymeric networks that are proficient in absorbing small to large drug molecules. Thus, it is highly utilized in drug delivery applications. It becomes one of the potential drug delivery systems due to its biocompatibility and biodegradable properties along with an organized release profile. There were several studies conducted across the globe to develop the COVID-19 vaccine and some studies are still going on to develop an effective vaccine with the help of hydrogels, which showcase the future applications and opportunities of hydrogel-based drug delivery systems.

These hydrogel-based delivery systems leverage various therapeutically beneficial results of drug delivery and also showcase several clinical uses. Hydrogels offer spatial & temporal control throughout the release of several therapeutic agents that includes macromolecular drugs, small-molecule drugs, and cells. Due to the controllable degradability, tunable physical properties, and ability to preserve labile drugs from degradation, hydrogels operate as a platform where several physiochemical connections with the encapsulated drugs control their release.

ADVERTISEMENT

COVID-19 Impact Analysis

The global COVID-19 pandemic has impacted the growth of almost every sector and economy of nations across the globe. The imposed lockdown, travel ban, and other norms have significantly affected various domains of businesses. However, the COVID-19 as positively impacted the hydrogel-based drug delivery system market as various clinical trials of the vaccines require hydrogel, which is contributing its market growth.

In addition, there are many pharma companies that are highly using hydrogel to carry out their research activities regarding new drug development and other clinical studies. Due to this, the demand for hydrogel-based drug delivery systems in the market has increased and further creating new growth avenues for the global market over the forecast period.

Market Growth Factors:

Therapeutic values of the hydrogel-based drug delivery system

In the therapeutic field, drug delivery approaches need exceptional enhancements in developing safe transport systems to attain the required therapeutic effect and to eliminate the side effects. Biomimetic strategies including polymers explain advanced industrial products orientated to aimed therapy and controlled release.

Increasing clinical trials of various medicines, therapies, and vaccines

There are an increasing number of diseases prevailing across the globe, which needs proper medication facilities to improve patients' health. In addition, the growing prevalence of chronic diseases is contributing to the increased demand for better medications, therapies, and vaccines. The outbreak of the global pandemic has also accelerated the number of clinical trials going on across the globe.

Market Restraining Factor:

Complicated manufacturing process

The development process of these hydrogel-based drug delivery systems with constant surface area is very complex, which is estimated to hamper the growth of the market. In addition, it becomes difficult for the companies to manufacture these systems for further usage due to their complex design. It is expected to further restrict the adoption of these systems by various companies.

Polymer Origin Outlook

Based on Polymer Origin, the market is segmented into Synthetic, Natural and Hybrid. Hydrogel-based drug delivery systems are manufactured by using synthetic polymer and are becoming more popular with wide acceptance than naturally derived polymer due to the greater drug absorbing capability, improved lifetime, enhanced mechanical properties, and controllable degradation features. Poly starch, vinylpyrrolidone, and acrylic acid are broadly utilized synthetic polymers in drug delivery applications.

Delivery Route Outlook

Based on Delivery Route, the market is segmented into Ocular, Subcutaneous, Oral Cavity, Topical and Other Delivery Routes. The ocular segment garnered the maximum revenue share in the hydrogel-based drug delivery system marker in 2020. Hydrogels are generally utilized in ocular drug delivery applications as the hard and contact lenses are manufactured with the help of hydrogel films. Thus, it becomes easy to include therapeutic drugs into contact lenses.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia Pacific region is anticipated to register the fastest growth rate in the hydrogel-based drug delivery system during the forecast period. The existence of a huge target population, enhancing access to healthcare, boosting demand for improved medical care in several therapeutic fields, and growing demand to reduce healthcare costs are among the major factors surging the market growth during the forecast period. Nations like India, China, and South Korea are some of the major markets, which is expected to create bright growth prospects in this region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Bausch Health Companies, Inc., Medtronic PLC, Galderma S.A., Endo International PLC, Ferring Holdings SA, Akorn Operating Company LLC, Tolmar Pharmaceuticals, Inc., Blairex Laboratories, Inc., and Ocular Therapeutix, Inc.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Hydrogel-based Drug Delivery System Market by Polymer Origin
3.1 Global Synthetic Market by Region
3.2 Global Natural Market by Region
3.3 Global Hybrid Market by Region

Chapter 4. Global Hydrogel-based Drug Delivery System Market by Delivery Route
4.1 Global Ocular Market by Region
4.2 Global Subcutaneous Market by Region
4.3 Global Oral Cavity Market by Region
4.4 Global Topical Market by Region
4.5 Global Other Delivery Routes Market by Region

Chapter 5. Global Hydrogel-based Drug Delivery System Market by Region

Chapter 6. LAMEA Hydrogel-based Drug Delivery System Market

Chapter 7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental &Regional Analysis
7.1.4 Research & Development Expenses
7.2 Bausch Health Companies, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Medtronic PLC
7.3.1 Company overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.4 Galderma S.A.
7.4.1 Company Overview
7.4.2 Recent strategies and developments:
7.4.2.1 Partnerships, Collaborations, and Agreements:
7.4.2.2 Approvals & Trials:
7.5 Endo International PLC
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental Analysis
7.5.4 Research & Development Expenses
7.6 Ferring Holdings SA
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research and Development Expense
7.7 Akorn Operating Company LLC
7.7.1 Company Overview
7.7.2 Recent strategies and developments:
7.7.2.1 Approvals & Trials:
7.8 Tolmar Pharmaceuticals, Inc.
7.8.1 Company Overview
7.9 Blairex Laboratories, Inc.
7.9.1 Company Overview
7.10. Ocular Therapeutix, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:
7.10.4.2 Approvals & Trials:

For more information about this report visit https://www.researchandmarkets.com/r/fweunp

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900